SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC)

被引：2
|
作者：
Spiera, Robert [1 ]
Hummers, Laura [2 ]
Chung, Lorinda [3 ]
Frech, Tracy [4 ]
Domsic, Robin [5 ]
Hsu, Vivian [6 ]
Furst, Daniel [7 ,8 ]
Gordon, Jessica [1 ]
Mayes, Maureen [9 ]
Simms, Robert [10 ]
Lee, Elizabeth [11 ]
Constantine, Scott [11 ]
Dgetluck, Nancy [11 ]
White, Barbara [11 ]
机构：
[1] Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA
[2] Johns Hopkins, Baltimore, MD USA
[3] Stanford Univ, Palo Alto, CA 94304 USA
[4] Univ Utah, Salt Lake City, UT USA
[5] Univ Pittsburgh, Pittsburgh, PA USA
[6] Univ Med & Dent New Jersey, New Brunswick, NJ USA
[7] Pacific Arthrit Associates, Los Angeles, CA USA
[8] Univ Calif Los Angeles, Los Angeles, CA USA
[9] Univ Texas Houston, Houston, TX USA
[10] Boston Univ, Boston, MA 02215 USA
[11] Corbus Pharmaceut Inc, Norwood, MA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3390
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
OP0325
引用
收藏
页码：245 / 245
页数：1
相关论文
共 50 条
  • [1] Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
    Spiera, Robert F.
    Hummers, Laura K.
    Chung, Lorinda
    Frech, Tracy M.
    Domsic, Robyn T.
    Hsu, Vivien
    Furst, Daniel E.
    Gordon, Jessica K.
    Mayes, Maureen D.
    Simms, Robert W.
    Lee, Elizabeth
    Constantine, Scott
    White, Barbara
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [2] Safety and Efficacy of Lenabasum at 21 Months in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
    Spiera, Robert
    Hummers, Laura
    Chung, Lorinda
    Frech, Tracy
    Domsic, Robyn
    Hsu, Vivien
    Furst, Daniel
    Gordon, Jessica
    Myers, Madeline
    Simms, Robert W.
    Lee, Elizabeth
    Constantine, Scott
    Dgetluck, Nancy
    Bloom, Bradley
    White, Barbara
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [3] SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS
    Werth, Victoria
    Pearson, David
    Owaka, Joyce
    Feng, Rui
    Concha, Josef Simon
    Patel, Basil
    Hejazi, Emily
    Cornwall, Caitlin
    Constantine, Scott
    Dgetluck, Nancy
    White, Barbara
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 199 - 200
  • [4] Safety and Efficacy of Anabasum (JBT-101) in Diffuse Cutaneous Systemic Sclerosis (dcSSc) Subjects Treated in an Open-Label Extension of Trial JBT101-SSc-001
    Spiera, Robert F.
    Hummers, Laura K.
    Chung, Lorinda
    Frech, Tracy M.
    Domsic, Robyn T.
    Hsu, Vivien
    Furst, Daniel E.
    Gordon, Jessica K.
    Mayes, Maureen D.
    Simms, Robert W.
    Constantine, Scott
    White, Barbara
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [5] SAFETY AND EFFICACY OF LENABASUM (JBT-101) IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS TREATED FOR ONE YEAR IN AN OPEN-LABEL EXTENSION OF TRIAL JBT101-SSC-001
    Spiera, R.
    Hummers, L.
    Chung, L.
    Frech, T.
    Domsic, R.
    Hsu, V.
    Furst, D. E.
    Gordon, J.
    Mayes, M.
    Simms, R.
    Lee, E.
    Dgetluck, N.
    Constantine, S.
    White, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 52 - 52
  • [6] Safety and Efficacy of Lenabasum at Week 68 in an Open-Label Extension of a Phase 2 Study of Lenabasum in Refractory Skin-Predominant Dermatomyositis (DM) Subjects
    Werth, Victoria
    Pearson, David
    Okawa, Joyce
    Feng, Rui
    Concha, Josef
    Patel, Basil
    Hejazi, Emily
    Constantine, Scott
    Dgetluck, Nancy
    White, Barbara
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [7] Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial
    Chung, Lorinda
    Spino, Cathie
    McLain, Richard
    Johnson, Sindhu R.
    Denton, Christopher P.
    Molitor, Jerry A.
    Steen, Virginia D.
    Lafyatis, Robert
    Simms, Robert W.
    Kafaja, Suzanne
    Frech, Tracy M.
    Hsu, Vivien
    Domsic, Robyn T.
    Pope, Janet E.
    Gordon, Jessica K.
    Mayes, Maureen D.
    Sandorfi, Nora
    Hant, Faye N.
    Bernstein, Elana J.
    Chatterjee, Soumya
    Castelino, Flavia V.
    Ajam, Ali
    Allanore, Yannick
    Matucci-Cerinic, Marco
    Whitfield, Michael L.
    Distler, Oliver
    Singer, Ora
    Young, Amber
    Nagaraja, Vivek
    Fox, David A.
    Furst, Daniel E.
    Khanna, Dinesh
    LANCET RHEUMATOLOGY, 2020, 2 (12): : E743 - E753
  • [8] PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
    Spiera, R.
    Kuwana, M.
    Khanna, D.
    Hummers, L.
    Frech, T.
    Stevens, W.
    Gordon, J.
    Kafaja, S.
    Matucci-Cerinic, M.
    Distler, O.
    Lee, E. B.
    Levy, Y.
    Jun, J. B.
    Constantine, S.
    Dgetluck, N.
    White, B.
    Furst, D.
    Denton, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 102 - 103
  • [9] Baseline Subject Demographics and Disease Characteristics in a Phase 3 Study of Safety and Efficacy of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
    Spiera, Robert
    Dgetluck, Nancy
    Bloom, Bradley
    White, Barbara
    Denton, Christopher
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [10] Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study
    Smith, V.
    Van Praet, J. T.
    Vandooren, B.
    Van der Cruyssen, B.
    Naeyaert, J-M
    Decuman, S.
    Elewaut, D.
    De Keyser, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (01) : 193 - 197
12345